Venture Visionary Partners LLC Cuts Holdings in Novo Nordisk A/S $NVO

Venture Visionary Partners LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 94.1% in the third quarter, HoldingsChannel reports. The firm owned 4,732 shares of the company’s stock after selling 75,877 shares during the quarter. Venture Visionary Partners LLC’s holdings in Novo Nordisk A/S were worth $263,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. First Hawaiian Bank boosted its stake in shares of Novo Nordisk A/S by 0.6% in the 1st quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock worth $1,556,000 after buying an additional 142 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in Novo Nordisk A/S by 1.1% during the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock worth $944,000 after acquiring an additional 150 shares during the period. Werba Rubin Papier Wealth Management lifted its holdings in Novo Nordisk A/S by 4.1% during the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after acquiring an additional 173 shares during the period. Atwood & Palmer Inc. boosted its position in Novo Nordisk A/S by 31.8% in the second quarter. Atwood & Palmer Inc. now owns 737 shares of the company’s stock worth $51,000 after purchasing an additional 178 shares during the last quarter. Finally, Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 47.3% in the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after purchasing an additional 186 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO opened at $47.61 on Friday. The firm has a 50-day moving average price of $50.01 and a 200-day moving average price of $57.86. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $104.75. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $212.59 billion, a price-to-earnings ratio of 13.84 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. The Goldman Sachs Group lowered their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, November 28th. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Finally, Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.